Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBRL 37344, sodium salt
Description: β3 agonist
Chemical Name: (R*,R*)-(±)-4-[2-[(2-(3-Chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxyacetic acid, sodium salt
Purity: ≥98% (HPLC)
Biological Activity for BRL 37344, sodium salt
BRL 37344, sodium salt is a potent and selective β3 adrenoceptor agonist (Ki values are 287, 1750 and 1120 nM for β3, β1 and β2 receptors respectively).
Licensing Information
Sold with the permission of GlaxoSmithKline
Technical Data for BRL 37344, sodium salt
| M. Wt | 385.82 |
| Formula | C19H21NO4ClNa |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 127299-93-8 |
| PubChem ID | 16219010 |
| InChI Key | SNJIJYKMYQRHRC-WJKBNZMCSA-M |
| Smiles | [Na+].C[C@H](CC1=CC=C(OCC([O-])=O)C=C1)NC[C@H](O)C1=CC(Cl)=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for BRL 37344, sodium salt
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 38.58 | 100 |
Preparing Stock Solutions for BRL 37344, sodium salt
The following data is based on the product molecular weight 385.82. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.59 mL | 12.96 mL | 25.92 mL |
| 5 mM | 0.52 mL | 2.59 mL | 5.18 mL |
| 10 mM | 0.26 mL | 1.3 mL | 2.59 mL |
| 50 mM | 0.05 mL | 0.26 mL | 0.52 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for BRL 37344, sodium salt
References for BRL 37344, sodium salt
References are publications that support the biological activity of the product.
Arch et al (1984) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309 163 PMID: 6325935
Ayo Oriowo et al (1996) The selectivity in vitro of the sterioisomers of the beta-3 adrenoreceptor agonist BRL 37344. J.Pharmacol.Exp.Ther. 277 22 PMID: 8613923
Board et al (2000) BRL37344, but not CGP12177, stimulates fuel oxidation by soleus muscle in vitro. Eur.J.Pharmacol. 406 33 PMID: 11011029
Strosberg and Pietri-Rouxel (1996) Function and regulation of the β3-adrenoceptor. TiPS 17 373 PMID: 8979772
If you know of a relevant reference for BRL 37344, sodium salt, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BRL 37344, sodium salt, BRL 37344, sodium salt supplier, β3-adrenoceptor, b3-adrenoceptor, agonists, β3-adrenergic, b3-adrenergic, Receptors, BRL37344, sodium, salt, GlaxoSmithKline, GSK, Adrenergic, Beta-3, 0948, Tocris Bioscience
10 Citations for BRL 37344, sodium salt
Citations are publications that use Tocris products. Selected citations for BRL 37344, sodium salt include:
Rankovic et al (2011) Modulation of calcium-dependent inactivation of L-type Ca2+ channels via β-adrenergic signaling in thalamocortical relay neurons. PLoS One 6 e27474 PMID: 22164209
Suárez et al (2014) Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech 7 129 PMID: 24159189
Lavine et al (2013) Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism. JAMA Ophthalmol 131 376 PMID: 23303344
Lavine (2017) β2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression. Invest Ophthalmol Vis Sci 58 299 PMID: 28114591
Littmann et al (2015) Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands. Dev Neurosci 355 183 PMID: 26306764
Briones et al (2005) Direct demonstration of beta1- and evidence against beta2- and beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. Br J Pharmacol 146 679 PMID: 16113691
Maupoil et al (2007) Ectopic activity in the rat pulmonary vein can arise from simultaneous activation of alpha1- and beta1-adrenoceptors. Br J Pharmacol 150 899 PMID: 17325650
Brahmadevara et al (2004) ALpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 142 781 PMID: 15205310
Cirino et al (2003) Involvement of β 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. J Biol Chem 100 5531 PMID: 12707413
Steinle et al (2003) β 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Pharmacol Exp Ther 278 20681 PMID: 12670949
Do you know of a great paper that uses BRL 37344, sodium salt from Tocris? Please let us know.
Reviews for BRL 37344, sodium salt
There are currently no reviews for this product. Be the first to review BRL 37344, sodium salt and earn rewards!
Have you used BRL 37344, sodium salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.